FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Evaluation of the TiaoShenZhiAi Regimen for Patients With Ovarian Cancer Experiencing a Psychoneurological Symptom Cluster: Protocol for a Multicenter, Double-Blind, Randomized Controlled Trial. PMID 42284089 · JMIR Res Protoc · 2026-Jun-12 This is a clinical trial protocol for an ovarian cancer study with a randomized design and a drug-containing intervention. However, it is not an original formal-result report; it is a protocol without results. Furthermore, the primary efficacy endpoint is the remission rate of a psychoneurological symptom cluster at 3 months, not a primary/key time-to-event efficacy endpoint (e.g., OS, PFS). The secondary endpoint includes 1-year survival, but this is not sufficient as the primary/key endpoint for inclusion. The phase is not explicitly stated in the provided information, but even if inferred, the other critical criteria (original result report, primary time-to-event endpoint) are not met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant mFOLFOXIRI with or without cadonilimab versus mFOLFOX6 in locally advanced colorectal cancer: A randomized phase 2 trial (OPTICAL-2). PMID 42134324 · Med · 2026-Jun-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Quality of life and patient-reported outcomes after non-surgical management of early-stage endometrial cancer and endometrial hyperplasia with atypia: a long-term follow-up of the feMMe phase II randomized clinical trial. PMID 42413196 · Int J Gynecol Cancer · 2026-Jun-11 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Study Protocol of OLIGOPELVIS 2-GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer. PMID 42276876 · Eur Urol Oncol · 2026-Jun-11 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Surgery or radiotherapy for early-stage cancer study protocol for an emulated target trial of radical radiotherapy versus radical cystectomy, with either following neoadjuvant chemotherapy, for organ-confined muscle-invasive bladder cancer. PMID 42276804 · BMJ Open · 2026-Jun-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Yellow fever vaccination in healthy Gambian children of different ages to establish safety and immunogenicity of a booster dose: a open-label, non-randomised, single-site, phase 3 vaccine trial. PMID 42276083 · Lancet Infect Dis · 2026-Jun-11 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Anti-CD123 monoclonal antibodies as therapeutic agents for acute myeloid leukemia: a systematic review. PMID 42257293 · Expert Rev Hematol · 2026-Jun-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Evaluation of a virtual Ayurvedic whole-systems lifestyle intervention for quality of life in breast cancer survivors: An exploratory randomized controlled trial. PMID 42320450 · Explore (NY) · 2026-Jun-10 The record describes a randomized, exploratory pilot study of a non-drug, whole-systems Ayurvedic lifestyle intervention (ADRP) for quality of life in breast cancer survivors. It is a Phase II (pilot) trial, not Phase III/IIIb or Phase II/III. It lacks a drug intervention and does not report on any time-to-event efficacy endpoints (OS, PFS, DFS, etc.), focusing instead on patient-reported outcomes like quality of life, sleep, and digestive symptoms. Therefore, it does not meet the core eligibility criteria for inclusion in this oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis. PMID 42272192 · Acta Derm Venereol · 2026-Jun-10 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial. PMID 42268294 · Clin Cancer Res · 2026-Jun-10 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| High-Dose Intravenous Vitamin C and Mortality and Organ Dysfunction in Severe Burn Injury: The VICTORY Randomized Clinical Trial. PMID 42267875 · JAMA · 2026-Jun-10 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review. PMID 42265474 · Eur J Clin Pharmacol · 2026-Jun-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Faricimab: current evidence for the treatment of retinal vein occlusion. PMID 42265442 · Graefes Arch Clin Exp Ophthalmol · 2026-Jun-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial. PMID 42008768 · J Clin Oncol · 2026-Jun-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial. PMID 41576297 · J Clin Oncol · 2026-Jun-10 The trial is oncology, human, randomized, Phase III, has a drug intervention, and reports original primary results. However, it is excluded because the primary endpoint is pCR, which does not meet the time-to-event efficacy endpoint criterion (no OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR reported). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Mepolizumab Efficacy in COPD: Insights from Longitudinal Patterns of Blood Eosinophil Counts and Their Variability Across Three Clinical Trials. PMID 42265988 · Am J Respir Crit Care Med · 2026-Jun-09 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Transarterial Embolization Alone Versus Drug-Eluting Microspheres Chemoembolization for Hepatocellular Carcinoma (RAD-18-TAcE): A Multicenter Randomized Clinical Trial. PMID 42265476 · Cardiovasc Intervent Radiol · 2026-Jun-09 The record describes a randomized trial in oncology (hepatocellular carcinoma) with a primary time-to-event endpoint (TTP) and reports final results. However, the trial phase (e.g., Phase III) is not explicitly stated in the provided abstract or metadata, and the intervention (TAE vs. DEM-TACE) is a procedure-based comparison, not a drug-containing intervention where the drug is the primary component of the experimental arm. Therefore, eligibility criteria for both 'phase3_or_definitive' and 'drug_intervention' are not met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Continuation of first-line therapy with radiotherapy for oligoprogression versus early switch to second-line therapy in oligoprogressive hepatocellular carcinoma (CROSS): study protocol of a multicentre, randomised, controlled, open-label, phase III trial. PMID 42264528 · BMJ Open · 2026-Jun-09 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Duration of antibiotic therapy for bacteraemia in immune compromised hosts-a post-hoc subgroup analysis of the Bacteremia Antibiotic Length Actually Needed For Clinical Effectiveness (BALANCE) randomized clinical trial. PMID 42264033 · Clin Microbiol Infect · 2026-Jun-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| STAGE II NON-SMALL CELL LUNG CANCER: UPFRONT SURGERY OR NEOADJUVANT CHEMOIMMUNOTHERAPY. PMID 42264017 · Ann Thorac Surg · 2026-Jun-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Certolizumab inhibits radiographic progression in patients with early rheumatoid arthritis and high rheumatoid factor levels: A pooled, post-hoc analysis of the phase 3 C-EARLY and C-OPERA trials. PMID 42263998 · Joint Bone Spine · 2026-Jun-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Robotic versus open pancreatoduodenectomy (SPAIN Trial): protocol for a multicenter randomized controlled trial assessing safety, efficacy and cost-effectiveness. PMID 42262715 · Updates Surg · 2026-Jun-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Low-fat dietary pattern and dementia mortality: a secondary analysis of the Women's Health Initiative dietary modification randomized clinical trial with long-term follow-up. PMID 42262514 · Menopause · 2026-Jun-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| [Efficacy and safety of combining olorigliflozin with metformin in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy]. PMID 42252239 · Zhonghua Yi Xue Za Zhi · 2026-Jun-09 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke: The INSTANT Randomized Clinical Trial. PMID 42100960 · JAMA · 2026-Jun-09 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| IV Fosphenytoin for Acute Trigeminal Neuralgia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. PMID 42096672 · Neurology · 2026-Jun-09 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comparative Efficacy of First-Line Therapeutic Options for ES-SCLC: An Indirect Comparison Using IPDfromKM-Reconstructed Individual Patient Data. PMID 42352404 · Cancers (Basel) · 2026-Jun-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The Efficacy of Dexamethasone Versus N-Acetylcysteine in Prevention of Post-Embolization Syndrome in Hepatocellular Carcinoma Patients: A Multicenter Randomized, Double-Blind, Double-Dummy, Non-Inferiority Trial. PMID 42260068 · Asia Pac J Clin Oncol · 2026-Jun-08 The study is a randomized Phase 3 oncology trial with drug intervention, but its primary endpoint is the incidence of post-embolization syndrome (a complication/safety outcome) at 48 hours, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the core criterion for inclusion in a Kaplan-Meier digitization cohort. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety Profile of a Triple Single-Pill Combination of Valsartan/Amlodipine/Chlorthalidone in Patients with Uncontrolled Hypertension. PMID 42259717 · Clin Ther · 2026-Jun-08 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results. PMID 42309525 · J Crohns Colitis · 2026-Jun-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Final Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in IB-IIIA Non-Small-Cell Lung Cancer: Phase 2 neoSCORE Trial. PMID 42252705 · Cancer Sci · 2026-Jun-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis. PMID 42252377 · Diabetes Ther · 2026-Jun-07 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. PMID 42252333 · Nat Med · 2026-Jun-07 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. PMID 42251859 · Lancet Diabetes Endocrinol · 2026-Jun-07 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial. PMID 42251769 · JAMA · 2026-Jun-07 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. PMID 42251595 · JAMA · 2026-Jun-07 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comment on "Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study". PMID 42252027 · Am J Transplant · 2026-Jun-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Impact of Mavacamten on Disease-Related Symptoms in Patients With Obstructive Hypertrophic Cardiomyopathy: HCMSQ Outcomes in EXPLORER-HCM. PMID 42251960 · J Card Fail · 2026-Jun-06 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comparison of erector spinae plane, paravertebral, and pectoral nerve blocks on postoperative analgesia and Quality of Recovery-15 in patients undergoing mastectomy: a prospective randomized trial. PMID 42251440 · Perioper Med (Lond) · 2026-Jun-06 Study is a randomized trial in an oncology (breast cancer surgery) setting and reports a time-to-event endpoint. However, it is excluded because the intervention consists of regional anesthesia techniques (nerve blocks) and not a systemic or targeted drug therapy for treatment efficacy. The primary endpoint is total morphine consumption (a safety/analgesic endpoint), not a standard efficacy endpoint like OS/PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Early antiretroviral therapy and long-term cancer risk in HIV: 9-year outcomes from the START randomized trial. PMID 42251304 · BMC Cancer · 2026-Jun-06 The study is a well-conducted randomized trial with a drug intervention and time-to-event endpoint, but it does not meet the strict eligibility criteria because: 1) The phase of the trial is not explicitly established as Phase III/IIIb or Phase II/III in the provided abstract (though the START trial is a definitive trial, the phase is not stated here), and 2) This specific analysis is a long-term follow-up/secondary analysis of cancer outcomes rather than the primary trial result report. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase III maintenance telerehabilitation in elderly patients with chronic heart failure and type 2 diabetes (TELEMECHRON study). PMID 42250988 · Eur J Intern Med · 2026-Jun-06 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial. PMID 42214397 · Lancet · 2026-Jun-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study. PMID 42179186 · Oncologist · 2026-Jun-06 The study is a randomized Phase III trial of a drug combination in oncology with original results. However, the primary and key secondary endpoints are response rates (SVR and TSS reduction), which are categorical outcomes, not time-to-event endpoints (OS, PFS, DFS, EFS, RFS, TTP, or survival analysis with Kaplan-Meier or HR). Therefore, it does not meet the time-to-event efficacy criterion for this cohort. |
H
L
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. PMID 42119587 · Lancet · 2026-Jun-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Survival benefit of oral systemic monotherapy in previously treated metastatic colorectal cancer: a meta-analysis. PMID 42104118 · Oncologist · 2026-Jun-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Impact of Availability of Computer-Aided Detection Devices on Adenoma Detection During Colonoscopy: A Cluster Randomized Study. PMID 42250891 · Gastroenterology · 2026-Jun-05 Study is a cluster randomized pragmatic quality improvement study assessing the impact of a computer-aided detection device on adenoma detection rates during colonoscopy. While oncology-related, it lacks a drug intervention, is not a Phase III or Phase II/III trial, and does not report a primary time-to-event efficacy endpoint like OS, PFS, DFS, etc. Adenoma detection rate is an intermediate surrogate endpoint, not a time-to-event outcome. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Integrating multiple outcomes of first-line immunotherapy-based regimens for advanced hepatocellular carcinoma: A network meta-analysis of phase III trials. PMID 42250662 · Crit Rev Oncol Hematol · 2026-Jun-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer. PMID 42250604 · Ann Oncol · 2026-Jun-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence. PMID 42249801 · Oncotarget · 2026-Jun-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of fibrinogen concentrate (BT524) in severe hemorrhage: Phase 3 subcohort analysis of the AdFIrst trial in patients undergoing cytoreductive surgery for pseudomyxoma peritonei. PMID 42247815 · J Clin Anesth · 2026-Jun-05 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |